September 29, 2021
September 29, 2021 – The U.S. FDA has approved LivmarliTM (maralixibat) oral solution to treat cholestatic pruritus in patients who are at least one year old and have been
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Pharmacy Benefits Management
September 28, 2021
September 28, 2021
September 28, 2021 – Qulipta® (atogepant) from AbbVie has received FDA approval for the preventive treatment of episodic migraine in adults.
September 28, 2021
September 28, 2021 – Starting January 1, 2022, Eli Lilly will reduce the cost of all its non-branded insulin products. This includes the company's Insulin Lispro Injection
September 24, 2021
September 24, 2021 – The U.S. FDA has approved expanded indications for Repatha® (evolocumab). The drug is now indicated as an add-on treatment for patients
September 22, 2021
September 22, 2021 – Jakafi® (ruxolitinib) is now FDA approved to treat chronic graft-versus-host disease (cGVHD) in patients who are at least 12 years old and have failed
September 21, 2021
September 21, 2021 – Samsung Bioepis and Biogen's ByoovizTM (ranibizumab-nuna) has received U.S. FDA approval as a biosimilar for Genentech's Lucentis® (ranibizumab)
September 21, 2021
September 21, 2021 – OpzeluraTM (ruxolitinib) cream, manufactured by Incyte, has won U.S. FDA approval to treat mild to moderate atopic dermatitis in non-immunocompromised